Aditya Bardia
#151,586
Most Influential Person Now
Researcher
Aditya Bardia's AcademicInfluence.com Rankings
Aditya Bardiaengineering Degrees
Engineering
#6134
World Rank
#7441
Historical Rank
Biomedical Engineering
#516
World Rank
#526
Historical Rank
Applied Physics
#1915
World Rank
#1949
Historical Rank

Download Badge
Engineering
Aditya Bardia's Degrees
- Bachelors Biomedical Engineering Stanford University
Why Is Aditya Bardia Influential?
(Suggest an Edit or Addition)Aditya Bardia's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition (2013) (1854)
- Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis (2014) (1786)
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study (2020) (1264)
- Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells (2013) (938)
- Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility (2014) (789)
- A microfluidic device for label-free, physical capture of circulating tumor cell-clusters (2015) (568)
- Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. (2019) (527)
- Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. (2018) (518)
- Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. (2007) (444)
- Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer (2019) (427)
- Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models (2018) (316)
- HER2 expression identifies dynamic functional states within circulating breast cancer cells (2016) (304)
- Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: a case series. (2006) (299)
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. (2021) (297)
- Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis. (2016) (241)
- Efficacy of complementary and alternative medicine therapies in relieving cancer pain: a systematic review. (2006) (229)
- Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis (2020) (226)
- Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer (2017) (224)
- Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer (2019) (204)
- Efficacy of antioxidant supplementation in reducing primary cancer incidence and mortality: systematic review and meta-analysis. (2008) (172)
- Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence. (2015) (160)
- Diagnosis of obesity by primary care physicians and impact on obesity management. (2007) (154)
- Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future (2020) (153)
- Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis (2020) (144)
- Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment. (2007) (141)
- Tunable Nanostructured Coating for the Capture and Selective Release of Viable Circulating Tumor Cells (2015) (141)
- Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors (2017) (133)
- Use of herbs among adults based on evidence-based indications: findings from the National Health Interview Survey. (2007) (132)
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. (2017) (128)
- Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics (2017) (119)
- PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Kα inhibitors in breast cancer. (2019) (113)
- CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions (2019) (104)
- Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin‐Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations (2017) (102)
- Recreational physical activity and risk of postmenopausal breast cancer based on hormone receptor status. (2006) (101)
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. (2017) (99)
- Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study. (2016) (99)
- Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. (2017) (92)
- Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. (2007) (90)
- Using machine learning to parse breast pathology reports (2016) (90)
- Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study (2011) (88)
- Intercellular nanotubes mediate mitochondrial trafficking between cancer and immune cells (2021) (81)
- Biomarker Analyses in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer. (2021) (80)
- Neoadjuvant Therapy as a Platform for Drug Development and Approval in Breast Cancer (2013) (79)
- Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer (2018) (78)
- Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer. (2017) (77)
- Sacituzumab Govitecan, a Trop-2-Directed Antibody-Drug Conjugate, for Patients with Epithelial Cancer: Final Safety and Efficacy Results from the Phase 1/2 IMMU-132-01 Basket Trial. (2021) (76)
- Circulating tumor cells exhibit metastatic tropism and reveal brain metastasis drivers. (2019) (74)
- Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. (2009) (73)
- Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions. (2016) (73)
- Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer (2012) (71)
- A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer. (2018) (67)
- Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study. (2019) (66)
- Sacituzumab Govitecan in Previously Treated Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Final Results from a Phase 1/2, Single-Arm, Basket Trial. (2020) (65)
- Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. (2019) (65)
- Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. (2018) (62)
- Antibody–Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments (2017) (61)
- Novel antibody–drug conjugates for triple negative breast cancer (2020) (59)
- Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate. (2014) (58)
- HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial. (2019) (56)
- Body Size and Incident Colorectal Cancer: A Prospective Study of Older Women (2010) (55)
- Relative Weight at Age 12 and Risk of Postmenopausal Breast Cancer (2008) (54)
- LBA17 ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC) (2020) (53)
- ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer (2021) (51)
- Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study (2021) (51)
- 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials (2016) (51)
- Pharmacodynamic study of Disulfiram in Men with Non-metastatic Recurrent Prostate Cancer (2013) (50)
- Patient‐reported outcomes in women with breast cancer enrolled in a dual‐center, double‐blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor‐induced musculoskeletal symptoms (2014) (48)
- Abstract GS2-05: First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial (2018) (48)
- AR Expression in Breast Cancer CTCs Associates with Bone Metastases (2018) (46)
- Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies (2021) (46)
- Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab. (2021) (45)
- Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. (2018) (44)
- Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3‐Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations (2019) (44)
- Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer (2021) (42)
- Publication bias for CAM trials in the highest impact factor medicine journals is partly due to geographical bias. (2007) (42)
- Efficacy of nonestrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use: a pooled analysis (2009) (41)
- FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer (2019) (40)
- Abstract GS2-03: Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and mortality, stratified by breast cancer subtypes and adjuvant chemotherapy usage: Individual patient-level meta-analyses of over 27,000 patients (2019) (40)
- Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial (2022) (38)
- Comparison of tissue genotyping (TG) vs circulating tumor DNA (ctDNA) for selection of matched therapy and impact on clinical outcomes among patients with metastatic breast cancer (MBC). (2018) (38)
- TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer. (2020) (37)
- Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results. (2019) (37)
- EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer. (2019) (35)
- Hemodynamic signature of breast cancer under fractional mammographic compression using a dynamic diffuse optical tomography system. (2013) (34)
- Targeted Therapy for Premenopausal Women with HR+, HER2− Advanced Breast Cancer: Focus on Special Considerations and Latest Advances (2018) (33)
- Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors. (2018) (33)
- Mediastinal pancreatic pseudocyst with acute airway obstruction (2007) (32)
- Antiemetics for chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy. (2011) (30)
- HER 2 expression identifies dynamic functional states within circulating breast cancer cells (2016) (30)
- Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer (2018) (30)
- Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy (2020) (30)
- Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials. (2020) (29)
- Declining sex ratio: role of society, technology and government regulation in Faridabad district, Haryana. (2004) (28)
- Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results. (2019) (28)
- Non-azotemic refractory rickets in Indian children. (2005) (28)
- Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer. (2017) (28)
- Long-term outcome in children with primary distal renal tubular acidosis. (2005) (27)
- Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors (2020) (27)
- Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer (2021) (27)
- Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. (2021) (26)
- Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7) (2020) (26)
- Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial (2021) (25)
- Adjuvant chemotherapy for resected stage II and III colon cancer: comparison of two widely used prognostic calculators. (2010) (25)
- Targeted therapy for metastatic triple negative breast cancer: The next frontier in precision oncology (2017) (25)
- Treatment of obesity. (2007) (25)
- A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC). (2019) (25)
- Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1) (2021) (25)
- Phase Ib/II study of LEE011, everolimus, and exemestane in postmenopausal women with ER+/HER2-metastatic breast cancer. (2014) (24)
- Prognostic web‐based models for stage II and III colon cancer (2011) (24)
- Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial). (2020) (23)
- Relationship of established risk factors with breast cancer subtypes (2021) (23)
- Is a solitary inguinal lymph node metastasis from adenocarcinoma of the rectum really a metastasis? (2010) (23)
- Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting: results of two pilot trials. (2008) (22)
- Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer (2022) (22)
- Solidifying liquid biopsies: can circulating tumor cell monitoring guide treatment selection in breast cancer? (2014) (22)
- Normalization of compression-induced hemodynamics in patients responding to neoadjuvant chemotherapy monitored by dynamic tomographic optical breast imaging (DTOBI). (2017) (22)
- Precision medicine and personalized breast cancer: combination pertuzumab therapy (2014) (22)
- Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. (2019) (21)
- Tinnitus and Hyperacusis (2009) (21)
- LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) (2022) (20)
- A careful reassessment of anthracycline use in curable breast cancer (2021) (20)
- Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer (2018) (20)
- Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC). (2021) (19)
- 858PSacituzumab govitecan (IMMU-132) for patients with pretreated metastatic urothelial uancer (UC): interim results (2017) (19)
- AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer (2017) (19)
- Gene-Expression-Based Predictors for Breast Cancer (2015) (19)
- Abstract P6-13-01: Triplet therapy with ribociclib, everolimus, and exemestane in women with HR+/HER2– advanced breast cancer (2016) (19)
- A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance (2020) (19)
- Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2- metastatic breast cancer (mBC). (2018) (18)
- Abstract GS1-07: Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, as ≥3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results (2018) (18)
- Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis (2021) (18)
- Abstract 1439: Pathological complete response after neoadjuvant chemotherapy predicts improved survival in all major subtypes of breast cancer: systematic review and meta-analyses of over 18,000 patients (2016) (18)
- A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer. (2020) (18)
- Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer (2019) (18)
- Personalizing Aspirin Use for Targeted Breast Cancer Chemoprevention in Postmenopausal Women. (2016) (17)
- Sacituzumab Govitecan For Metastatic Triple Negative Breast Cancer: Clinical Overview And Management Of Potential Toxicities. (2021) (17)
- Optimizing Radiotherapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. (2020) (16)
- Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital (2016) (16)
- Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (2021) (16)
- Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC). (2021) (16)
- Abstract CT231: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with estrogen receptor+ HER2-, advanced/metastatic breast cancer (2015) (16)
- Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer (2021) (15)
- Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting. (2020) (15)
- Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC) (2018) (15)
- Phase (Ph) 2 stage 1 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor (AR) inhibitor, in women with advanced AR+ triple-negative breast cancer (TNBC) or estrogen receptor (ER)+ BC: CLARITY-01. (2017) (15)
- Abstract GS1-05: Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study (2022) (15)
- Abstract PD13-07: Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer (2021) (15)
- Serial single-cell genomics reveals convergent subclonal evolution of resistance as early-stage breast cancer patients progress on endocrine plus CDK4/6 therapy (2021) (14)
- Spinal intradural extraosseous Ewing's sarcoma (2011) (14)
- Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC): A phase Ib, multicenter, study. (2020) (14)
- 211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study (2022) (14)
- Personalizing cardiovascular disease prevention among breast cancer survivors (2012) (14)
- Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer (2021) (14)
- The Evolving Role of Circulating Tumor Cells in the Personalized Management of Breast Cancer: From Enumeration to Molecular Characterization (2014) (14)
- The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer (2020) (13)
- Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic (2020) (13)
- A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial (2018) (13)
- Abstract PD1-6: A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus (an mTOR inhibitor) in patients with stage II/III triple-negative breast cancer (TNBC) (2013) (13)
- A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC). (2015) (12)
- Temporal trends and outcomes among patients admitted for immune-related adverse events: A single-center retrospective cohort study from 2011-2018. (2021) (12)
- Clinical Validation of a Cell-Free DNA Gene Panel. (2019) (12)
- Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates. (2021) (12)
- AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). (2021) (12)
- Abstract GS6-05: Gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancer (2017) (12)
- Abstract OT3-2-07: Phase I study of ARN-810, a novel selective estrogen receptor degrader, in post-menopausal women with locally advanced or metastatic estrogen receptor positive breast cancer (2013) (12)
- LBA14 Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study (2021) (12)
- AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer (2022) (11)
- Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer and Emerging Therapeutic Opportunities. (2021) (11)
- Therapy of refractory/relapsed metastatic triple-negative breast cancer (TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience. (2015) (11)
- Abstract P1-19-03: JAVELIN PARP Medley, a phase 1b/2 study of avelumab plus talazoparib: Results from advanced breast cancer cohorts (2020) (11)
- Phase (Ph) 1 study of oral seviteronel (VT-464), a dual CYP17-Lyase (L) inhibitor and androgen receptor (AR) antagonist, in patients (pts) with advanced AR+ triple negative (TNBC) or estrogen receptor (ER)+ breast cancer (BC). (2016) (10)
- Abstract P6-18-06: Ribociclib treatment benefit in patients with advanced breast cancer with ≥1 dose reduction: Data from the MONALEESA-2, -3, and -7 trials (2019) (10)
- Phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) in combination with either tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with HR+, HER2- advanced breast cancer (aBC): MONALEESA-7. (2015) (10)
- Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer (2018) (10)
- Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role (2022) (10)
- Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial. (2022) (10)
- High-Content Biopsies Facilitate Molecular Analyses and Do Not Increase Complication Rates in Patients With Advanced Solid Tumors. (2017) (10)
- Pilot evaluation of aprepitant for the treatment of hot flashes. (2006) (10)
- Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer (2017) (10)
- Genomic Profiling of Premenopausal HR+ and HER2– Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib (2021) (10)
- NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types (2021) (9)
- Abstract PD7-07: Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (2020) (9)
- KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC). (2020) (9)
- Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer (2020) (9)
- Search Strategies for Retrieving Complementary and Alternative Medicine Clinical Trials in Oncology (2006) (9)
- Inpatient admissions related to immune-related adverse effects (irAE) among patients treated with immune checkpoint inhibitors for advanced malignancy: A tsunami is coming, but are we ready? (2018) (9)
- Phase Ib trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy and a CDK4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC). (2020) (9)
- LBA4 Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase I trial (2021) (9)
- Abstract PD3-06: Safety and efficacy of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in heavily pretreated patients with TNBC (2016) (9)
- Abstract OT-03-09: Trastuzumab deruxtecan (T-DXd; DS-8201) vs investigator’s choice of chemotherapy in patients with hormone receptor-positive (HR+), HER2 low metastatic breast cancer whose disease has progressed on endocrine therapy in the metastatic setting: A randomized, global phase 3 trial (DES (2021) (9)
- Evaluation of RAD1901, a novel investigational, selective estrogen receptor degrader (SERD), for the treatment of ER-positive (ER+) advanced breast cancer. (2017) (9)
- Trop-2 as a therapeutic target for the antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132), in patients (pts) with previously treated metastatic small-cell lung cancer (mSCLC). (2016) (8)
- Dietary supplement usage by patients with cancer undergoing chemotherapy: does prognosis or cancer symptoms predict usage? (2007) (8)
- Association between PIK3CA mutation status and development of brain metastases in HR+/HER2- metastatic breast cancer (2019) (8)
- AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer (2022) (8)
- Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with estrogen receptor (ER) positive (+) metastatic breast cancer (MBC) (B2151009). (2018) (8)
- Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer (2020) (8)
- Phase II study of ruxolitinib , a selective JAK 1 / 2 inhibitor , in patients with metastatic triple-negative breast cancer (2018) (8)
- Personalized Tamoxifen: A Step Closer but Miles To Go (2010) (8)
- Temporal Trends in Inpatient Oncology Census Before and During the COVID‐19 Pandemic and Rates of Nosocomial COVID‐19 Among Patients with Cancer at a Large Academic Center (2021) (7)
- Abstract PD7-05: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer (2020) (7)
- Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer (2021) (7)
- POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancer. (2020) (7)
- Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer (2018) (7)
- Phase I/II study of SAR439859, an oral selective estrogen receptor degrader (SERD), in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). (2020) (7)
- Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study. (2022) (7)
- Phase I/II trial of IMMU-132 (isactuzumab govitecan), an anti-Trop-2-SN-38 antibody drug conjugate (ADC): Results in patients with metastatic gastrointestinal (GI) cancers. (2015) (7)
- Levetiracetam for the treatment of hot flashes: a phase II study (2007) (7)
- Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative. (2020) (7)
- KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer. (2019) (7)
- Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer (2021) (7)
- Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis (2022) (7)
- Validation of target engagement using 18F-fluoroestradiol PET in patients undergoing therapy with selective estrogen receptor degrader, ARN-810 (GDC-0810) (2015) (7)
- Abstract PD1-13: Somatic BRCA mutation detection by circulating tumor DNA analysis in patients with metastatic breast cancer: Incidence and association with tumor genotyping results, germline BRCA mutation status, and clinical outcomes (2018) (7)
- Abstract PD13-07: Activity and biomarker analyses from a phase Ia/b study of giredestrant (GDC-9545; G) with or without palbociclib (palbo) in patients with estrogen receptor-positive, HER2-negative locally advanced/metastatic breast cancer (ER+/HER2- LA/mBC) (2022) (6)
- Treatment-related side effects and views about dosage assessment to sustain quality of life: Results of an advocate-led survey of patients with metastatic breast cancer (MBC). (2021) (6)
- 214MO Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study (2022) (6)
- VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results (2022) (6)
- Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan (2022) (6)
- Therapy of metastatic, non-small cell lung cancer (mNSCLC) with the anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132). (2016) (6)
- Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2–) operable breast cancer (BC). (2021) (6)
- Evaluation of endocrine resistance using ESR1 genotyping of circulating tumor cells and plasma DNA (2021) (6)
- Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC). (2021) (6)
- Abstract CT107: Ribociclib in combination with everolimus and exemestane in men and postmenopausal women with HR+/HER2− advanced breast cancer after progression on a CDK4/6 inhibitor: Efficacy and safety results from phase II of the TRINITI-1 study (2018) (6)
- Genetics to epigenetics: targeting histone deacetylases in hormone receptor-positive metastatic breast cancer. (2019) (6)
- Abstract OT-03-06: Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer (NeoSTAR) (2021) (6)
- Updated overall survival (OS) and quality of life (QoL) in premenopausal patients (pts) with advanced breast cancer (ABC) who received ribociclib (RIB) or placebo (PBO) plus goserelin and a nonsteroidal aromatase inhibitor (NSAI) in the MONALEESA-7 (ML-7) trial (2019) (6)
- Abstract OT2-07-06: Phase Ib study to assess the safety, tolerability, and clinical activity of gedatolisib in combination with palbociclib and either letrozole or fulvestrant in women with metastatic or locally advanced/recurrent breast cancer (B2151009) (2018) (5)
- Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors (2022) (5)
- Phase II study of ruxolitinib in patients with pStat3+ breast cancer. (2013) (5)
- Patient Preferences for Use of Archived Biospecimens from Oncology Trials When Adequacy of Informed Consent Is Unclear. (2019) (5)
- An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low). (2022) (5)
- Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy (2019) (5)
- Therapy of gastrointestinal malignancies with an anti-Trop-2-SN-38 antibody drug conjugate (ADC) (sacituzumab govitecan): Phase I/II clinical experience. (2015) (5)
- A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer. (2021) (5)
- 257P Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC) (2021) (5)
- TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer. (2021) (5)
- Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer. (2019) (5)
- Mechanism of Action and Clinical Impact of Ribociclib—Response (2017) (5)
- FGFR gene amplification and response to endocrine therapy in metastatic hormone receptor positive (HR+) breast cancer. (2017) (5)
- Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results. (2016) (5)
- 500 Triple blockade with LEE011, everolimus, and exemestane in women with ER+/HER2− advanced/metastatic breast cancer: results from a Phase Ib clinical trial (2014) (5)
- Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy? (2019) (5)
- Abstract GS3-01: GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting (2023) (5)
- Abstract GS3-06: Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer (2021) (5)
- Scarring moxibustion and religious scarification resulting in hepatitis C and hepatocellular carcinoma (2006) (5)
- Tumor genomics and response to CDK 4/6 inhibitors for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC). (2017) (4)
- Abstract A75: Circulating tumor cells in human breast cancer exhibit dynamic changes in epithelial and mesenchymal composition (2013) (4)
- 331P Impact of ribociclib (RIB) dose reduction on overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) in MONALEESA (ML) -3 and -7 (2020) (4)
- Phase Ib study to assess the safety, tolerability, and clinical activity of gedatolisib in combination with palbociclib and either letrozole or fulvestrant in women with metastatic or locally advanced/recurrent breast cancer (B2151009; NCT02684032). (2017) (4)
- Abstract P2-11-01: Safety and efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) as ≥3rd-line therapeutic option for treatment-refractory HER2-negative metastatic breast cancer (HER2Neg mBC) (2019) (4)
- Antibody-drug conjugates in breast cancer. (2017) (4)
- Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis. (2018) (4)
- A phase Ib, first-in-human, dose escalation and expansion study of XMT-1522, a novel antibody-drug conjugate (ADC) directed against HER2, in patients with advanced breast cancer and other advanced tumors expressing HER2. (2017) (4)
- Abstract OT2-11-09: Lidera breast cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy (ET) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+/HER2- EBC) (2022) (4)
- 168P Sacituzumab govitecan (SG) efficacy in patients with metastatic triple-negative breast cancer (mTNBC) by HER2 immunohistochemistry (IHC) status: Findings from the phase III ASCENT study (2022) (4)
- Abstract PD2-08: Ribociclib with endocrine therapy for premenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer: Biomarker analyses from the phase III randomized MONALEESA-7 trial (2019) (4)
- Therapy for chemopretreated metastatic urothelial cancer (mUC) with the antibody-drug conjugate (ADC) sacituzumab govitecan (IMMU-132). (2017) (4)
- Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID‐19 (2021) (4)
- Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2− Advanced Breast Cancer (2020) (4)
- Abstract OT2-07-05: A phase III, randomized trial of sacituzumab govitecan (IMMU-132) vs treatment of physician choice (TPC) for metastatic triple-negative breast cancer (mTNBC) (2018) (4)
- Severe immune-related adverse effects (irAE) requiring hospital admission in patients treated with immune checkpoint inhibitors for advanced malignancy: Temporal trends and clinical significance. (2018) (4)
- In-depth gene expression analysis of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib-containing therapy in the Phase III MONALEESA-7 trial. (2019) (4)
- Abstract PS11-09: Impact ofUGT1A1status on the safety profile of sacituzumab govitecan in the phase 3 ASCENT study in patients with metastatic triple-negative breast cancer (2021) (4)
- Abstract P6-18-04: Ribociclib with a non-steroidal aromatase inhibitor and goserelin in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESA-7 age subgroup analysis (2019) (4)
- LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer. (2016) (4)
- Abstract P5-19-27: IMMU-132, a new antibody-drug conjugate (ADC) against Trop-2, as a novel therapeutic for patients with relapsed/refractory, metastatic, triple-negative breast cancer (TNBC): Results from Phase I/II clinical trial (NCT01631552) (2015) (4)
- Sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study. (2022) (4)
- Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer (2022) (4)
- 276O Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2, -3, and -7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptor–positive, HER2-negative (HR+/HER2−) advanced breast cancer (ABC) (2020) (4)
- Therapy of advanced metastatic lung cancer with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience. (2015) (4)
- The Art of Oncology: COVID‐19 Era (2020) (4)
- A prostate cancer clinical trials consortium trial of disulfiram (D) in men with nonmetastatic recurrent prostate cancer (PCa). (2013) (4)
- Abstract P2-08-04: Phase 1/2 study of oral seviteronel (VT-464), a dual CYP17-lyase inhibitor and androgen receptor (AR) antagonist, in patients with advanced AR positive triple negative (TNBC) or estrogen receptor (ER) positive breast cancer (BC) (2017) (4)
- Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer (2020) (4)
- Abstract P6-18-14: Patient-reported outcomes with ribociclib-based therapy in hormone receptor-positive, HER2-negative advanced breast cancer: results from the phase III MONALEESA-2, -3, and -7 trials (2019) (3)
- Impact of ribociclib (RIB) dose modifications (mod) on overall survival (OS) in patients (pts) with HR+/HER2- advanced breast cancer (ABC) in MONALEESA(ML)-2. (2022) (3)
- Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer (2022) (3)
- 264P AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) (2021) (3)
- Case 35-2018: A 68-Year-Old Woman with Back Pain and a Remote History of Breast Cancer. (2018) (3)
- Locally recurrent secretory carcinoma of the breast. (2021) (3)
- Measures of functional status in adults aged ≥70 years with advanced breast cancer (ABC) receiving palbociclib (PAL) combination therapy in POLARIS (2019) (3)
- 233P Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials (2021) (3)
- Abstract P1-13-01: Phase I study of ARN-810, a novel and potent oral selective estrogen receptor degrader, in postmenopausal women with metastatic estrogen receptor positive (ER+), HER2- breast cancer (2015) (3)
- Abstract CT064: Treatment for metastatic platinum-resistant urothelial cancer (PRUC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): phase I/II clinical experience (2016) (3)
- Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. (2022) (3)
- Reconstructing tumor trajectories during therapy through integration of multiple measurement modalities (2021) (3)
- Incidence of peripheral edema in patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer (2019) (3)
- A systematic literature review of the clinical prognosis of HR+/HER2- advanced or metastatic breast cancer with and without PIK3CA mutation. (2018) (3)
- Bizarre big belly ball: intraabdominal abscess mimicking stauffer syndrome secondary to uterine leiomyosarcoma. (2007) (3)
- Personal breast: customizing agents and biomarkers for optimal adjuvant endocrine therapy (2010) (3)
- Circulating tumor cell (CTC) and CA2729 as predictors of outcome in patients with metastatic breast cancer (MBC) in the prospective TBCRC 005 biomarker study. (2010) (3)
- Localised prostate cancer - What the medical oncologist needs to know (2011) (3)
- Cost of inpatient admissions for immune-related adverse effects from immune checkpoint inhibitor therapy: A single center experience. (2018) (3)
- 144P Neoadjuvant giredestrant (GDC-9545) + palbociclib (P) vs anastrozole (A) + P in postmenopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Biomarker subgroup analysis of the randomised, phase II coopERA BC study (2022) (3)
- Abstract P3-14-03: A phase 1b study of the CDK4/6 inhibitor ribociclib in combination with the PD-1 inhibitor spartalizumab in patients with hormone receptor-positive metastatic breast cancer (HR+ MBC) and metastatic ovarian cancer (MOC) (2020) (3)
- Abstract P5-11-01: Phamacodynamic and circulating tumor DNA evaluation in a phase I study of GDC-0927, a selective estrogen receptor antagonist/ degrader (SERD) (2019) (3)
- Impact of PIK3CA tumor mutation on the association of aspirin or NSAID use and time to breast cancer recurrence. (2017) (3)
- Abstract P5-13-02: Neoadjuvant endocrine therapy for estrogen receptor (ER) positive breast cancer: Comprehensive systematic review and meta-analysis (2016) (3)
- Abstract PD13-06: Neoadjuvant giredestrant (GDC-9545) + palbociclib versus anastrozole + palbociclib in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer: Primary analysis of the randomized, open-label, phase II coopERA breast cancer study (2022) (3)
- 277MO SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/ HER2- metastatic breast cancer (mBC): Biomarker analyses from a phase I/II study (2020) (3)
- Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open-label randomized phase II trial. (2022) (2)
- Abstract P5-19-08: IMMU-132, a potential new antibody-drug conjugate (ADC) for the treatment of triple-negative breast cancer (TNBC): Preclinical and initial clinical results (2015) (2)
- EMERALD: A randomized, open label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901) versus investigator’s choice (IC) of endocrine therapy (ET) for ER+/HER2- advanced breast cancer (BC) following CDK4/6 inhibitor (CDK4/6i) therapy. (2019) (2)
- Abstract PD13-02: Phase Ib expansion study of gedatolisib in combination with palbociclib and endocrine therapy in women with ER+ metastatic breast cancer (2022) (2)
- Randomized phase II trial of venetoclax + fulvestrant versus fulvestrant in estrogen receptor+, HER2– locally advanced or metastatic breast cancer following recurrence or progression during or after a CDK4/6 inhibitor: VERONICA. (2019) (2)
- Cancer-Associated Neuropathic Pain and Paraneoplastic Syndromes (2012) (2)
- Phase 1/2 dose-escalation and expansion study investigating SAR439859 +/- palbociclib in postmenopausal women with estrogen receptor-positive (ER+)/HER2- metastatic breast cancer. (2019) (2)
- Abstract OT2-03-03: Evaluation of talazoparib, a PARP inhibitor, in patients with somaticBRCAmutant metastatic breast cancer: Genotyping based clinical trial (2020) (2)
- Supporting Patients with Cancer after Dobbs v. Jackson Women’s Health Organization (2022) (2)
- Abstract P4-22-15: Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate (ADC) for the treatment of relapsed/refractory, metastatic triple-negative breast cancer (mTNBC): Updated results (2017) (2)
- Physical activity and risk of postmenopausal breast cancer defined by hormone receptor status and histology: A large prospective cohort study with 18 years of follow up. (2006) (2)
- Pharmacogenomics of Tamoxifen: Ready for Prime Time? (2010) (2)
- 66-year-old woman with painless vesicular lesions. (2009) (2)
- Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer: Phase 1b clinical trial. (2017) (2)
- Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2- breast cancer (LEADER). (2020) (2)
- Abstract P6-18-39: Abemaciclib after prior palbociclib exposure in patients with metastatic hormone-receptor positive (HR+)/HER2- breast cancer (2019) (2)
- Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer (2022) (2)
- Abstract 2638: Sacituzumab Govitecan, combination with PARP inhibitor, Talazoparib, in metastatic triple-negative breast cancer (TNBC): Translational investigation (2022) (2)
- Abstract CT236: Advanced solid cancer therapy with a novel antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): key preclinical and clinical results (2015) (2)
- 1553O Health-related quality of life (HRQoL) in the phase III TROPiCS-02 trial of sacituzumab govitecan (SG) vs chemotherapy in HR+/HER2- metastatic breast cancer (MBC) (2022) (2)
- Abstract OT3-05-03: POLARIS: Palbociclib (P) in hormone receptor-positive (HR+) advanced breast cancer: A prospective multicenter noninterventional study (2018) (2)
- First report of real-world patient characteristics and treatment patterns from POLARIS: Palbociclib in hormone receptor-positive (HR+) advanced breast cancer: A prospective, multicenter, noninterventional study. (2018) (2)
- Antibody drug conjugates for patients with breast cancer. (2021) (2)
- Abstract CT069: Baseline gene expression patterns of CDK4/6 inhibitor-naïve or -refractory HR+, HER2- advanced breast cancer in the phase Ib study of ribociclib plus everolimus plus exemestane (2018) (2)
- Abstract CT110: Ribociclib in combination with everolimus and exemestane in men and postmenopausal women with HR+/HER2− advanced breast cancer following progression on a CDK4/6 inhibitor: Safety, tolerability, and pharmacokinetic results from Phase 1 of TRINITI-1 study (2017) (2)
- Ribociclib Plus Endocrine Therapy in Premenopausal Women (2018) (2)
- Abstract OT2-01-05: TRINITI-1: Ribociclib + everolimus (EVE) + exemestane (EXE) triplet combination in men or postmenopausal women with HR+, HER2– advanced breast cancer (ABC) following progression on a cyclin-dependent kinase (CDK) 4/6 inhibitor (2017) (2)
- Images in clinical medicine. Intratracheal melanoma metastases. (2006) (2)
- Abstract P1-13-03: Association of PIK3CA mutation with clinical response to specific endocrine therapies in metastatic hormone receptor positive (HR+) breast cancer (2015) (2)
- Abstract GS2-02: Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial (2022) (2)
- P4-12-13: A Multi-Center Randomized Controlled Double Blind Trial Assessing the Effect of Acupuncture in Reducing Musculoskeletal Symptoms in Breast Cancer Patients Taking Aromatase Inhibitors: First Interim Analysis. (2011) (2)
- Abstract OT3-05-06: EarLEE-2: A phase 3 study of ribociclib + endocrine therapy (ET) for adjuvant treatment of patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), intermediate-risk, early breast cancer (EBC) (2018) (2)
- Breast Cancer Index (BCI) and prediction of pathological complete response (pCR) to neoadjuvant chemotherapy in estrogen receptor positive (ER+) breast cancer. (2018) (2)
- 179TiP EMERALD: A randomized, open-label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine therapy for ER+/HER2- advanced breast cancer following CDK4/6 inhibitor therapy (2020) (2)
- Identification of putative germline mutations in 10,288 patients undergoing circulating tumor DNA testing. (2017) (2)
- O3.1Targeting the estrogen receptor: old receptor, new drug(s) (2015) (2)
- Abstract LB-C16: Safety and tumor responses of the anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in refractory, metastatic, triple-negative breast cancer (TNBC): An ongoing Phase II trial (2015) (2)
- Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptorpositive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): additional results from the MONALEESA-7 trial (2018) (2)
- The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer (2022) (2)
- Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion (2021) (2)
- Dose-escalation study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal women with ER+/HER2- metastatic breast cancer (mBC). (2019) (2)
- Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC). (2021) (2)
- Abstract P1-19-06: Patient-reported outcomes, including work productivity, from the MONALEESA-7 trial of ribociclib plus endocrine therapy in patients with HR+/HER2− advanced breast cancer (2020) (2)
- Sacituzumab govitecan (SG) in patients (pts) with previously treated metastatic endometrial cancer (mEC): results from a phase I/II study. (2020) (2)
- Abstract P1-17-11: Updated data from AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), combined with palbociclib in postmenopausal women with ER+/HER2- advanced breast cancer (2022) (2)
- Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), versus investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC). (2022) (2)
- Sacituzumab Govitecan in Metastatic Breast Cancer. Reply. (2021) (2)
- Digoxin as an inhibitor of global hypoxia inducible factor-1α (HIF1α) expression and downstream targets in breast cancer: Dig-HIF1 pharmacodynamic trial. (2013) (2)
- Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer (2022) (1)
- Abstract OT3-04-03: KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk early-stage ER+/HER2–breast cancer (2019) (1)
- A closer look at sacituzumab govitecan-hziy. (2020) (1)
- Triplet Combination of Endocrine Therapy with CDK 4/6 Inhibitor, Ribociclib, and MTOR Inhibitor, Everolimus in HR+, HER2-ABC: Results from the Dose-Expansion Cohort (2017) (1)
- Abstract OT2-08-01: A phase 1b trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy with/without CDK 4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC) (2020) (1)
- Abstract 3734: Pharmacokinetics of sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) targeting Trop-2, in patients with diverse advanced solid tumors (2017) (1)
- Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series (2022) (1)
- Flu vaccination rate of patients with severe immune-related adverse events. (2019) (1)
- Elacestrant may improve outcomes for patients whose metastatic breast cancers progressed on prior endocrine therapy (2022) (1)
- Abstract P6-10-03: Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple-Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study (2023) (1)
- Phase II trial of a PARP inhibitor in somatic BRCA mutant metastatic breast cancer. (2020) (1)
- Abstract P2-02-18: Higher mutation burden and mutant allele fraction of circulating tumor DNA corresponds to worse progression free survival in metastatic breast cancer patients (2018) (1)
- SWISH-ing steroids: new standard of care to prevent everolimus-induced oral mucositis? (2017) (1)
- Sex ratio in India (2006) (1)
- Abstract CT087: Ribociclib + endocrine therapy (ET) doublet combinations in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Phase I clinical activity and impact of molecular alterations (2017) (1)
- Association of angiotensin II blockers with survival among men with prostate cancer: Results from CaPSURE. (2011) (1)
- A phase II study evaluating efficacy of zoledronic acid in prevention of aromatase inhibitor (AI)-associated musculoskeletal symptoms: The ZAP trial. (2014) (1)
- Abstract PL06-04: Molecular characterization of circulating tumor cells. (2013) (1)
- The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population (2020) (1)
- Abstract PD13-03: Ribociclib, everolimus, exemestane triplet therapy in HR+/HER2− advanced breast cancer after progression on a CDK4/6 inhibitor: Final efficacy, safety, and biomarker results from TRINITI-1 (2022) (1)
- Does efficacy of non-estrogenic therapies for hot flashes among women vary by breast cancer history and tamoxifen use? A pooled analysis (2008) (1)
- Convergent evolution of resistance pathways during early stage breast cancer treatment with combination cell cycle (CDK) and endocrine inhibitors (2021) (1)
- Abstract P4-01-06: Elacestrant (RAD1901) inhibits growth of ex vivo cultured circulating tumor cells derived from hormone receptor-positive metastatic breast cancer (mBC) patients including those harboring ESR1 mutations (2020) (1)
- 356TiP A phase II/III, open-label, randomized trial of pembrolizumab + olaparib vs. pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy in locally recurrent inoperable or metastatic triple-negative breast cancer: KEYLYNK-009 (2020) (1)
- Abstract P5-16-11: Ipatasertib (ipat) in combination with palbociclib (palbo) and fulvestrant (fulv) in patients (pts) with hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC) (2022) (1)
- 1977 Synergy of LCL161, an antagonist of inhibitor of apoptosis proteins (IAPs), with paclitaxel in a gene expression signature-enriched cohort of triple-negative breast cancer (TNBC) (2015) (1)
- Abstract PD13-07: PD13-07 Combination therapy with the AKT inhibitor, ipatasertib, endocrine therapy, and a CDK4/6 inhibitor for hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC): results from the phase I TAKTIC trial (2023) (1)
- Abstract P5-23-04: Men with advanced breast cancer (BC): Initial phase (Ph) 2 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor (AR) inhibitor (2018) (1)
- KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer (2019) (1)
- Phase II multicenter study of talazoparib for somatic BRCA1/2 mutant metastatic breast cancer. (2021) (1)
- Abstract CT141: Genetic landscape of premenopausal HR+/HER2- advanced breast cancer (ABC) based on comprehensive circulating tumor DNA analysis and association with clinical outcomes in the Phase III MONALEESA-7 trial (2019) (1)
- Neoadjuvant single and dual HER2 blockade among patients with localized HER2-positive breast cancer. (2013) (1)
- 358TiP Phase Ib/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancer (2020) (1)
- Landscape of BRCA1 and BRCA2 germline, somatic, and reversion alterations detectable by cell-free DNA testing among patients with metastatic breast, ovarian, pancreatic, or prostate cancer. (2018) (1)
- Assessment of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) cohort by agent in the phase 3 ASCENT study of patients (pts) with metastatic triple-negative breast cancer (mTNBC). (2021) (1)
- persevERA Breast Cancer (BC): Phase III study evaluating the efficacy and safety of giredestrant (GDC-9545) + palbociclib versus letrozole + palbociclib in patients (pts) with estrogen-receptor-positive, HER2-negative locally advanced or metastatic BC (ER+/HER2– LA/mBC). (2021) (1)
- Analysis of prognostic (prog) Web-based models for stage II and III colon cancer (CC): A population-based validation of Numeracy (NUM) and ADJUVANT! Online (ADJ!). (2009) (1)
- Persistence of AKT1 low quiescent cancer cells after neoadjuvant chemotherapy in triple negative breast cancer patients. (2017) (1)
- Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer (2021) (1)
- Abstract OT3-02-06: Femara plus ribociclib or placebo as neo-adjuvant endocrine therapy for women with ER+, HER2-negative early breast cancer - The Feline trial (2017) (1)
- Research Biopsies: An integrative review of the experiences of patients with cancer (2018) (1)
- Abstract P1-12-03: Association between tumor genotype and development of brain metastases in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer (2017) (1)
- Abstract P5-11-07: Real-world predictors of first-line treatment and descriptive outcomes in HR+/HER2−metastatic breast cancer patients in the US (2020) (1)
- Abstract PS5-10:Esr1mutation as a potential predictor of abemaciclib benefit following prior cdk4/6 inhibitor (cdk4/6i) progression in hormone receptor-positive (hr+) metastatic breast cancer (mbc): A translational investigation (2021) (1)
- TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer. (2022) (1)
- ABSTRACTS 32nd Annual Meeting • American Society of Preventive Oncology, Bethesda, Maryland • March 16-18, 2008 (2008) (1)
- Abstract P4-10-09: Patient-centered dosing: Oncologists’ perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC) (2022) (1)
- Clinical outcomes of patients with stage IV cancer receiving immune checkpoint inhibitors in the inpatient setting. (2019) (1)
- Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) who received prior chemotherapy (CT): MONALEESA-7 subgroup analysis. (2018) (1)
- Abstract PD2-03: Association between co-existing genomic alterations and abemaciclib benefit in patients with metastatic hormone receptor-positive breast cancer with ESR1 mutations following disease progression on prior endocrine therapy plus palbociclib or ribociclib (2022) (1)
- 91O Pooled analysis of patient (pt)-reported outcomes (PROs) in the MONALEESA (ML)-2, -3, and -7 trials: Additional results and key subgroup findings (2021) (1)
- Intratracheal Melanoma Metastases (2006) (1)
- Abstract P4-20-07: Research biopsies in oncology-patient willingness, perceptions, understanding, and experience: An integrative review (2017) (1)
- Comparison of the cell-free DNA genomics in patients with metastatic breast cancer (MBC) who develop brain metastases versus those without brain metastases. (2020) (1)
- Landscape of GATA3 mutations identified from circulating tumor DNA clinical testing and their impact on disease outcomes in estrogen receptor-positive (ER+) metastatic breast cancers treated with endocrine therapies. (2021) (1)
- Abstract OT2-07-01: A phase 2 study of futibatinib (TAS-120) in metastatic breast cancers harboring fibroblast growth factor receptor (FGFR) amplifications (FOENIX-MBC2) (2020) (1)
- Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network (2022) (1)
- Mechanisms of Resistance to Antibody–Drug Conjugates (2023) (1)
- Adjuvant abemaciclib for high-risk breast cancer: the story continues. (2021) (1)
- Emre Ozkumur Sorting of Rare Circulating Tumor Cells Independent − Dependent and − Inertial Focusing for Tumor Antigen (2013) (1)
- Abstract PD2-05: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2- advanced breast cancer (ABC) across the MONALEESA (ML) studies (2022) (1)
- Molecular alterations in the Ras-Raf-Erk (MAPK) pathway in metastatic hormone receptor positive (HR+)/HER2- breast cancer: Incidence and impact on clinical outcomes. (2018) (1)
- Abstract PD5-04: Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage breast cancer (2018) (1)
- Impact of multidisciplinary severe immunotherapy complication service on outcomes for cancer patients receiving immune checkpoint inhibition. (2021) (1)
- Trastuzumab for small HER-2+ breast cancer: small tumor, big decision. (2012) (1)
- AMEERA-5: A randomized, double-blind phase III study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer. (2021) (1)
- Abstract P2-14-17: A phase 1b study of PVX-410 vaccine in combination with pembrolizumab in metastatic triple negative breast cancer (mTNBC) (2022) (1)
- 220P Elacestrant vs fulvestrant or aromatase inhibitor (AI) in phase III trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), vs standard of care (SOC) endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC): Subgroup analysis from EMERALD (2022) (1)
- Uncovering the differential impact of ESR1 and PIK3CA codon variants on the clinical phenotype of metastatic breast cancer (MBC) through circulating tumor DNA (ctDNA) next-generation sequencing (NGS). (2021) (1)
- Abstract PD13-08: PD13-08 Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/HER2–Negative Breast Cancer (BC) (2023) (1)
- Abstract P4-10-15:PIK3CAmutational analysis using cell-free DNA next-generation sequencing detects activating mutations that may be missed with targeted hot-spot testing (2020) (1)
- Efficacy and Safety of Self Expanding Metal Stents (SEMS) in Alleviating Combined Malignant Biliary and Duodenal Obstruction: A Nine Year Tertiary Center Experience (2006) (1)
- Abstract 1903: PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Ká inhibitors in breast cancer (2020) (1)
- Feasibility of integrating the Outcomes4Me smartphone navigation application into the care of breast cancer patients (FIONA). (2021) (1)
- Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer (2019) (0)
- Abstract PD13-04: PD13-04 Exploratory subgroup and biomarker analyses of acelERA Breast Cancer: Phase II study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy for previously treated, estrogen receptor+, HER2– advanced breast cancer (2023) (0)
- P01.02 Trastuzumab Deruxtecan Plus Pembrolizumab in Advanced/Metastatic Breast or Non-Small Cell Lung Cancer: A Phase 1b Study (2021) (0)
- Acknowledgement of reviewers 2015 (2016) (0)
- Chabner Colloquium: Answering the Big Questions in Cancer Research & 2017 STO Annual Meeting (2017) (0)
- P-162Interim Results of IMMU-132 (Sacituzumab Govitecan), an Anti-Trop-2 Antibody-Drug Conjugate (ADC), in Patients (pts) with Metastatic Gastrointestinal (GI) Cancers (2015) (0)
- Abstract PD6-08: Exploring the interplay among ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype of metastatic breast cancer (MBC) through circulating tumor DNA (ctDNA) next-generation sequencing (NGS) (2022) (0)
- Decision-Analytic Modeling Studies: An Overview for Clinicians Using Dlbcl As An Example. (2015) (0)
- Abstract P2-07-02: Genomic predictors of rapid progression to first line endocrine and CDK4/6 inhibitor combination therapy in patients with estrogen receptor positive (ER+) HER-2 negative (HER2-) advanced breast cancer (ABC) (2022) (0)
- Abstract OT2-11-08: AMEERA-5 : A randomized, double-blind phase 3 study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer (2022) (0)
- Adult Weight Gain and Risk of Developing Non-Hodgkin Lymphoma (NHL): Results from a Large Prospective Cohort Study of Older Women. (2006) (0)
- 1629OA systematic rapid autopsy program tracks temporal and spatial heterogeneity of human tumors and identifies mechanisms of resistance to targeted therapies (2017) (0)
- Acknowledgement of reviewers 2014 (2014) (0)
- Abstract HER2-19: HER2-19 Impact of HER2 low status on clinical outcomes in participants with 1-3 positive lymph nodes, HR+/HER2- breast cancer with recurrence score </25 randomized to endocrine therapy +/- chemotherapy: results from SWOG S1007 (RxPONDER) (2023) (0)
- Current and Emerging Role of Antibody-Drug Conjugates in HER2-Negative Breast Cancer. (2023) (0)
- Abstract PS17-02: Molecular alterations in the androgen receptor and associated clinical outcomes in hormone receptor-positive/HER2- metastatic breast cancer (2021) (0)
- Detection of microsatellite instability high (MSI-H) status by targeted plasma-based genotyping in metastatic breast cancer (2022) (0)
- Mipomersen For Treatment Of Hypercholesteremia: Evidence Review And Meta Analytic Evaluation Of Randomized Controlled Trials (2015) (0)
- Abstract PD17-03: Cell-free DNA monitoring in a phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor ribociclib for localized HR+/HER2- breast cancer (LEADER) (2023) (0)
- Abstract PD5-08: Not presented (2018) (0)
- Abstract OT1-03-04: Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators’ choice of chemotherapy in previously-treated, inoperable or metastatic HR+/HER2– breast cancer: TROPION-Breast01 (2023) (0)
- AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer (2017) (0)
- Reply to R. Nishihara et al. (2022) (0)
- Abstract PD9-06: Paired pre- and post-treatment DNA sequencing identifies genomic alterations mediating clinical resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer (2019) (0)
- Abstract PD17-08: Pooled gene expression analysis and association with treatment response in patients with HR+/HER2− advanced breast cancer in the MONALEESA-2, -3, and -7 trials (2023) (0)
- Abstract P1-12-01: Withdrawn (2018) (0)
- Abstract 1736: A novel RNA-based assay for the detection and monitoring of circulating tumor cell signatures in breast cancer (2017) (0)
- NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types (2021) (0)
- Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer. Reply. (2019) (0)
- Obesity and Obesity Management Not Being Documeented (2008) (0)
- Healthcare medical costs among post-menopausal women with hormone receptor positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC) managed with systemic therapy following CDK 4/6 inhibitor (CDKi) in the real-world setting. (2018) (0)
- Changes in patient-reported outcomes in women with breast cancer in a multicenter double-blind randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms (AIMSS). (2012) (0)
- Association of pathologic complete response following neoadjuvant chemotherapy with survival among young women with breast cancer. (2012) (0)
- Abstract OT1-4-04: A phase II randomized, open-label, neoadjuvant study of LCL161, an oral antagonist of inhibitor of apoptosis proteins, in combination with paclitaxel in patients with triple-negative breast cancer (2013) (0)
- Abstract P3-14-02: Upper extremity edema in the at-risk arm among patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer (2019) (0)
- Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2. (2022) (0)
- Abstract OT1-07-05: TROPiCS-02: phase 3 study of Sacituzumab Govitecan (IMMU-132) in relapsed/refractory hormonal receptor-positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC) (2020) (0)
- Abstract P1-13-07: Investigating NF1 Mutations in Circulating Tumor DNA of Patients with Hormone-receptor Positive (HR+) Breast Tumors Resistant to CDK4/6 Inhibition (CDK4/6i): A Retrospective Clinical Analysis (2023) (0)
- Abstract P2-05-11: Not presented (2018) (0)
- Abstract P3-23-02: Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer receiving CDK 4/6 inhibitors (2022) (0)
- Impact of single and dual neoadjuvant HER2-directed therapy on clinical outcomes among patients with HER2-positive breast cancer (BC). (2013) (0)
- Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis. (2023) (0)
- Abstract P4-03-04: Dynamic tomographic optical breast imaging (TOBI) for neoadjuvant chemotherapy monitoring (2016) (0)
- Abstract 960: Overlapping expression landscape of antibody drug conjugate targets, trophoblast cell surface antigen 2 (Trop-2) & human epidermal growth factor receptor 2 (HER2), in breast cancer (2023) (0)
- Progress in the treatment of breast cancer: increased survival, improved patient experience, and advances in drug formulation. (2023) (0)
- Levetiracetam for the treatment of hot flashes: A pilot study (2007) (0)
- Abstract PD13-02: PD13-02 Exploratory gene expression analysis of coopERA Breast Cancer (BC): a study evaluating neoadjuvant giredestrant versus anastrozole alone and in combination with palbociclib in ER-positive, HER2-negative untreated early BC (2023) (0)
- Abstract CT517: Amcenestrant, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/HER2- advanced breast cancer (aBC): combined biomarker analyses from a Phase 1/2 study in postmenopausal women and a Phase 1 study in postmenopausal Japanese women (2022) (0)
- Patient attitudes towards biobanks and preferences for use of archived biospecimens. (2018) (0)
- Neoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial (2019) (0)
- Abstract P3-07-08: Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in HR+/HER2- metastatic breast cancer (MBC) (2023) (0)
- Abstract P5-02-22: Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving the Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib: Biomarker Results from POLARIS (2023) (0)
- Chabner Colloquium: Answering the Big Questions in Cancer Research & 2018 STO Annual Meeting (2018) (0)
- Abstract PS7-02: The relationship of established breast cancer risk factors with breast cancer subtypes (2021) (0)
- 31st Annual Meeting • American Society of Preventive Oncology, Houston, Texas • March 2–4, 2007 (2007) (0)
- Feasibility of introducing a smartphone navigation application into the care of breast cancer patients (The FIONA Study) (2023) (0)
- Abstract 6744: Cell-free DNA detection of alterations in the MAPK pathway in metastatic hormone receptor positive breast cancer: A multi-institutional analysis of incidence and clinical outcomes (2023) (0)
- Abstract OT2-24-03: Phase II study of a PARP inhibitor in metastatic breast cancer with somaticBRCA1/2mutations identified by cell-free DNA: Genotyping based clinical trial (2022) (0)
- Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma (2023) (0)
- Abstract 4353: Utilizing scRNA sequencing to understand biomarkers of response and resistance to Sacitizumab Govetican in localized TNBC (2023) (0)
- Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer (2022) (0)
- Pooled Analysis of Safety and Dose Reductions in the MONALEESA-2, -3, and -7 Phase III Trials on Ribociclib Plus Endocrine Therapy to Treat Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (2020) (0)
- Abstract P4-01-42: Pooled analysis of post-progression treatments after first-line ribociclib + endocrine therapy in patients with HR+/HER2− advanced breast cancer in the MONALEESA-2, -3, and -7 studies (2023) (0)
- Utilizing Natural Language Processing (NLP) to identify breast cancer associated-lung metastases from pathology reports to delineate characteristics and challenges of this common site of breast cancer recurrence. (2022) (0)
- 116TiPMONALEESA-7: a phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) combined with standard first-line endocrine therapy (ET) for the treatment of premenopausal women with HR + , HER2– advanced breast cancer (aBC) (2015) (0)
- Case 8-2023: A 71-Year-Old Woman with Refractory Hemolytic Anemia. (2023) (0)
- 68TiP KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC (2020) (0)
- 274TiP Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators’ choice of chemotherapy (ICC) in previously-treated, inoperable or metastatic hormone-receptor (HR) positive, HER2-negative (HR+/HER2–) breast cancer: TROPION-Breast01 (2022) (0)
- Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53 (2023) (0)
- Abstract P4-14-01: Whole exome sequencing reveals greater intratumor genetic heterogeneity in primary breast cancer arising in African American compared to Caucasian women (2015) (0)
- A careful reassessment of anthracycline use in curable breast cancer (2021) (0)
- Patient-centered dosing: oncologists’ perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC) (2022) (0)
- Abstract CT073: Efficacy of novel oral SERD elacestrant in fulvestrant-refractory hormone receptor-positive (HR+) breast cancer: a translational investigation (2023) (0)
- A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression. (2023) (0)
- Abstract PD9-07: Genomic landscape of metastatic breast cancer (MBC): Comprehensive cell-free DNA analysis from over 10,000 patients and comparison with primary breast cancer (2021) (0)
- Abstract P6-10-08:AKT1alterations following exposure to endocrine-based therapy in patients with hormone-receptor positive (HR+) metastatic breast cancer (MBC): Clinical and functional implications (2020) (0)
- Abstract PS18-18: Microsatellite instability high (MSI-H) detection utilizing targeted plasma based genotyping in metastatic breast cancer (2021) (0)
- Can Physical Activity Reduce The Risk of Breast Cancer? (2007) (0)
- Abstract P5-20-02: HER2 mutations detected by ctDNA in ER+/HER2- metastatic breast cancer patients: Incidence and impact on clinical outcomes (2018) (0)
- Abstract P1-15-01: Withdrawn (2019) (0)
- Abstract OT-09-06: Phase II neoadjuvant study of GDC-9545 + palbociclib (palbo) vs anastrozole (A) + palbo in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2- eBC) (2021) (0)
- Abstract PD14-04: Circulating tumor DNA characterization of invasive lobular carcinoma in patients with metastatic breast cancer (2022) (0)
- Abstract P6-18-15: Ribociclib + endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled safety analysis (2019) (0)
- Abstract OT-30-02: Phase II study of talazoparib, a PARP inhibitor, in somaticBRCA1/2mutant metastatic breast cancer (2021) (0)
- Abstract P1-18-22: AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation (2022) (0)
- Abstract OT1-04-05: Phase 1/2 dose-escalation and expansion study investigating SAR439859, a potent, oral, selective estrogen receptor degrader, +/- palbociclib in metastatic breast cancer (2020) (0)
- Abstract 443: Blood-based genotyping and clinical outcomes in patients with advanced breast cancer receiving the CDK4/6 inhibitor palbociclib in real-world settings: Results from POLARIS (2019) (0)
- Limitations of “Evidence-Based Indications” for Herbs–Reply–I (2007) (0)
- Mechanisms of Resistance to CDK4/6 Inhibitors in Hormone Receptor-Positive (HR +) Breast Cancer: Spotlight on Convergent CDK6 Upregulation and Immune Signaling (2022) (0)
- Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer (2022) (0)
- Patient and disease characteristics of women with acute myelogenous leukemia (AML) and a history of breast cancer (BC). (2010) (0)
- Abstract P1-14-02: Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2- breast cancer (LEADER, part 1) (2022) (0)
- Abstract 5248: CDK4/6 inhibition (CDK4/6i) is effective in the real-world setting for hormone receptor-positive metastatic breast cancer (HR+ MBC) with ESR1 mutations and fusions (2022) (0)
- Does antioxidant supplementation reduce primary cancer incidence and mortality?: Systematic review and meta analysis. (2006) (0)
- OT1-01-01: Prospective Clinical Trial Evaluating Efficacy of Zoledronic Acid (ZA) Prophylaxis for Prevention of Aromatase Inhibitor Associated Musculoskeletal Symptoms: ZAP-AIMSS Trial. (2011) (0)
- 258P Analysis of patients (pts) without an initial triple-negative breast cancer (TNBC) diagnosis (Dx) in the phase III ASCENT study of sacituzumab govitecan (SG) in brain metastases-negative (BMNeg) metastatic TNBC (mTNBC) (2021) (0)
- Abstract OT1-12-05: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer (2022) (0)
- Abstract OT2-03-02: lidERA Breast Cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy in patients with estrogen receptor+, HER2– early breast cancer (2023) (0)
- Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models (2018) (0)
- Genomic landscape of primary breast cancer in black vs. white women and association with tumor recurrence. (2015) (0)
- Cancer Pain Control with Traditional Chinese Medicine (2010) (0)
- Abstract P4-01-14: Changes in the Genomic Spectrum of Actionable Alterations in HER2 Negative Metastatic Breast Cancer in Serial Cell Free DNA (cfDNA) Analysis (2023) (0)
- Sex ratio in India [letter] (2006) (0)
- Abstract P5-01-06: Cell-free DNA (cfDNA) analysis of ESR1-mutant advanced breast cancer (aBC): Impact of subsequent therapy on mutation persistence (2020) (0)
- Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison (2023) (0)
- Clinical implementation of tumor genotyping to guide development of personalized regimens for patients with metastatic breast cancer: Challenges and opportunities (2016) (0)
- Correction: 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials (2019) (0)
- Acknowledgement of reviewers 2015 (2015) (0)
- Volume 22 Acknowledgments (2017) (0)
- Abstract P4-07-65: Effect of sacituzumab govitecan vs chemotherapy in HR+/HER2- metastatic breast cancer: patient-reported outcomes from the TROPiCS-02 trial (2023) (0)
- Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer (2023) (0)
- A Phase I Study of Adjuvant Niraparib Administered Concurrently with Postoperative Radiation Therapy in Patients with Localized Triple Negative Breast Cancer (2022) (0)
- Abstract P2-01-14: circulating tumor cells in breast cancer exhibit dynamic changes in epithelial and mesenchymal cell composition (2012) (0)
- ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer (2021) (0)
- Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy (2020) (0)
- Abstract GS1-11: Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC): Efficacy by Trop-2 Expression in the TROPiCS-02 Study of Patients (Pts) With HR+/HER2– Metastatic Breast Cancer (mBC) (2023) (0)
- Abstract P5-21-10: Phase 2 study and correlative analyses of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic, triple-negative breast cancer (2018) (0)
- Abstract LB033: Longitudinal ctDNA changes in patients with long-term response to palbociclib combination therapy for advanced breast cancer: A preliminary analysis from the real-world POLARIS study (2021) (0)
- Abstract PD10-01: PD10-01 Impact of ESR1 mutations on Selective Estrogen Receptor Degraders and Modulators: an integrated liquid-biopsy and pharmacodynamics approach (2023) (0)
- Abstract P2-01-01: Genetic alterations detected by circulating tumor DNA (ctDNA) in HER2-low metastatic breast cancer (MBC) (2022) (0)
- Limitations of evidence-based indications for herbs. Authors' reply (2007) (0)
- Tolerability and effectiveness of pertuzumab-containing neoadjuvant (NA) regimens vs. AC-TH for HER2-positive (+) localized breast cancer (BC). (2016) (0)
- TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis (2023) (0)
- Abstract P2-14-19: Surgical and long-term outcomes of patients receiving neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer (2019) (0)
- Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis (2022) (0)
- Abstract P4-01-06: Comparison of tumor genotyping and cell-free circulating tumor DNA sequencing in metastatic breast cancer patients and their utility in the selection of matched therapy (2019) (0)
- Abstract OT2-01-03: ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in women and men with metastatic breast cancer (mBC) (2023) (0)
- HER2-Low Breast Cancer-Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast. (2023) (0)
- P416 EVALUATION OF THE ROLE OF CELLULAR ANTIOXIDANT ENZYMES IN HEPATITIS C VIRUS (HCV) REPLICATION (2014) (0)
- Abstract OT2-11-03: AMEERA-1 : Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+/human epidermal growth factor receptor 2-negative (HER2-)PIK3CA-mutated advanced breast cancer (2022) (0)
- Abstract 3173: AKT1lowquiescent cancer cells persist after neoadjuvant chemotherapy in triple-negative breast cancer patients (2017) (0)
- Cost Effectiveness Of Statins In Primary Prevention Of Coronary Heart Disease: A Systematic Review And Quality Assessment Of Economic Evidence To Elucidate Recent Trends In Usa (2015) (0)
- Abstract OT3-25-01: Neoadjuvant HER2-targeted Therapy +/- Immunotherapy with Pembrolizumab (neoHIP): An Open Label Randomized Phase II Trial (2023) (0)
- Abstract P1-05-05: Comparison of genotyping results from tissue and circulating DNA (ctDNA) in patients with metastatic breast cancer (2017) (0)
- Abstract OT2-11-04: Ameera-1 Arm 5: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with abemaciclib in postmenopausal women with ER+/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (2022) (0)
- Impact of Tumour Genomics on Response to Standard Neo-adjuvant Chemotherapy in Triple-Negative Breast Cancer (2022) (0)
- Abstract OT1-11-01: Phase II study of talazoparib, a PARP inhibitor, in somatic BRCA1/2 mutant metastatic breast cancer identified by cell-free DNA or tumor tissue genotyping (2023) (0)
- Abstract SP012: Convergent evolution of resistance pathways during early stage breast cancer treatment with combination cell cycle (CDK) and endocrine signaling inhibitors (2021) (0)
- Acknowledgement of reviewers 2019 (2020) (0)
- Abstract P2-08-06: A phase 1 study of RAD1901, a novel, oral selective estrogen receptor degrader, for the treatment of ER-positive advanced breast cancer (2017) (0)
- Reply to G.-F. Li et al, K. Altundag, and N. SG et al. (2023) (0)
- Abstract P3-09-11: Clinical characteristics associated withBRCA1/2mutations identified on routine tumor tissue genotyping in metastatic breast cancer (2022) (0)
- 333TiP AMEERA-1: Phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) PIK3CA-mutated advanced breast cancer (2021) (0)
- Abstract PS18-19: Comparison of metastatic genomic profile in patients ≤45 years and patients >45 years with triple-negative breast cancer (2021) (0)
- Second Medical Opinions in the Era of Personalized Medicine (2015) (0)
- Abstract P5-16-07: Assessment of sacituzumab govitecan (SG) in Black patients (pts) from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC) (2022) (0)
- P018 TROPION-Breast03: Datopotamab deruxtecan (Dato-DXd) ± durvalumab vs investigator’s choice of therapy (ICT) for triple-negative breast cancer (TNBC) with residual disease following neoadjuvant therapy (2023) (0)
- Abstract P5-11-02: Dose-escalation study of SAR439859, an oral selective estrogen receptor degrader, in postmenopausal women with estrogen receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (2020) (0)
- 275TiP ASCENT-03: Phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in first-line (1L) metastatic triple-negative breast cancer (mTNBC) (2022) (0)
- Abstract P1-08-01: Virtual molecular and precision medicine (vMAP) clinic to improve access to clinical trials for patients with metastatic breast cancer: an academic-community collaboration (2023) (0)
- Abstract IA18: Molecular signatures of circulating tumor cells (2020) (0)
- Abstract P4-08-08: Genomic progression, detected by circulating tumor DNA (ctDNA) sequencing, as an early predictor of disease progression in metastatic breast cancer (MBC) (2019) (0)
- Abstract 3023: Dissecting mechanisms of breast cancer metastasis through patient-derived circulating tumor cells (2018) (0)
- Abstract P5-02-14: Identification of mechanisms of acquired resistance to ribociclib plus endocrine therapy using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials (2023) (0)
- Abstract 962: Multiplexed mutational profiling of breast tumor as an efficient clinical tool for personalized breast cancer treatment (2012) (0)
- Abstract P5-14-09: Comparison of cell-free DNA genomics of breast cancer associated-chest wall disease vs. age & subtype matched controls with metastatic breast cancer not involving the chest wall (2023) (0)
- Abstract P5-16-15: Post-progression therapy outcomes in patients (pts) from the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC) (2022) (0)
- Abstract P2-05-10: Withdrawn (2018) (0)
- Risk of multiple primary melanomas. (2006) (0)
- Abstract PD1-10: Impact of Race on Clinical, Socioeconomic, and Genomic Characteristics, Clinical Trial Participation, and Receipt of Genotype-matched Therapy Among Patients with Metastatic Breast Cancer (2023) (0)
- Abstract SY30-01: Molecular characterization of single circulating tumor cells. (2013) (0)
- Adjuvant chemotherapy for resected stage II and III colon cancer: Comparison of widely used two prognostic calculators. (2009) (0)
- Highlights in metastatic breast cancer from the European Society for Medical Oncology Virtual Congress 2020: commentary. (2020) (0)
- Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Using Dynamic Tomographic Optical Breast imaging (DTOBI) (2014) (0)
- Abstract PD8-06: Attitudes towards use of archived biospecimens among patients with cancer (2018) (0)
- Highlights in metastatic breast cancer from the European Society for Medical Oncology Virtual Congress 2020. (2020) (0)
- Abstract P4-09-06: Brain metastases (BM) in patients with metastatic breast cancer (MBC) and circulating cell-free DNA (cfDNA) somaticBRCAmutations (2020) (0)
- Abstract P5-16-16: Role of tumor microenvironment, as assessed by breast MRI background parenchymal enhancement (BPE), in modulating response to neoadjuvant chemotherapy in young women with localized breast cancer (2017) (0)
- Severe Lactic Acidosis Complicated by Insulin-Resistant Hyperosmolar Hyperglycemic Syndrome in a Patient With Metastatic Breast Cancer Undergoing AKT-Inhibitor Therapy. (2022) (0)
- Correlation of Triglycerides and Acute Pancreatitis: a Systematic Evidence Review. (2015) (0)
- Abstract P6-18-10: A phase 1b/2 study of ribociclib plus trastuzumab for the treatment of advanced, treatment-refractory HER2-positive breast cancer (2019) (0)
- Clinical application of liquid biopsies to detect somatic BRCA1/2 mutations and guide potential therapeutic intervention for patients with metastatic breast cancer (2021) (0)
- Abstract P5-01-05: Genomic alterations detected by circulating tumor DNA and correlation with response to treatment with elacestrant, an oral selective estrogen receptor degrader, in phase 1 trials in postmenopausal women with ER+/HER2- advanced/metastatic breast cancer (2020) (0)
- Abstract GS2-03: GS2-03 TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer (2023) (0)
- Prochlorperazine and 5HT3 antagonists for the treatment of breakthrough chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy. (2010) (0)
- Abstract P5-13-06: Exploratory biomarker analysis in VERONICA, a phase 2 study of venetoclax + fulvestrant versus fulvestrant in patients with estrogen receptor (ER)-positive HER2-negative metastatic breast cancer (mBC) (2022) (0)
- Abstract P5-16-01: Assessment of health-related quality of life by clinical response from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC) (2022) (0)
- Abstract LB-192: Circulating tumor cell clusters are precursors of breast cancer metastasis (2014) (0)
- Abstract P6-17-35: Withdrawn (2019) (0)
- Abstract P5-02-07: Cell-free DNA detection of GATA3 mutations in metastatic hormone receptor positive breast cancer: a retrospective, observational multi-institutional analysis (2023) (0)
- Abstract P1-18-05: Early changes in circulating tumor DNA and its effect on clinical outcomes in patients with advanced breast cancer receiving the CDK4/6 inhibitor palbociclib: Genotyping results from POLARIS (2022) (0)
- Abstract P4-12-08: Accuracy of Patient Self-Reported Breast Cancer Disease Characteristics Compared to the Medical Record in a Trial of the Outcomes4MeDigital Health App (2022) (0)
- Abstract P1-06-03: Serial evolution of hormone receptor status and mutational profile among patients with metastatic breast cancer (2017) (0)
- Abstract P6-10-10: Genetic alterations in breast cancer associated with MDM2 dependency and sensitivity to the MDM2 inhibitor milademetan (2023) (0)
- Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer (2018) (0)
- Abstract P4-02-01: Normalization of compression-induced hemodynamics in patients responding to neoadjuvant chemotherapy using dynamic tomographic optical breast imaging (TOBI) (2013) (0)
- Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) (2021) (0)
- Abstract SY24-01: High-throughput CTC detection for noninvasive cancer monitoring (2017) (0)
- Biomarker analysis from a phase I study using gedatolisib+palbociclib+hormone therapy in ER+/HER2- metastatic breast cancer (mBC). (2020) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Aditya Bardia?
Aditya Bardia is affiliated with the following schools:
- California Institute of Technology
- University of California, San Diego
- National Taiwan University
- Baylor University
- Massachusetts General Hospital
- Duke University
- Paris-Saclay University
- Complutense University of Madrid
- University of British Columbia
- Vanderbilt University
- Stanford University
- Johns Hopkins University
- Harvard University